Next Generation Proteomics Highlights

We have entered a new era in proteomics at large scale. We can now reliably identify and quantify thousands of proteins in thousands of samples for clinical biomarker validation. We can also now map cell-wide drug binding sites for target validation. Read more in the latest article from our CEO and co-founder Oliver Rinner.

Understanding the target of a small molecule compound is the key to gaining a deeper insight into its mechanism of action and potential toxicities. Watch this webinar with our scientific advisor, Prof. Paola Picotti (ETH Zürich), as well as Nigel Beaton and Oliver Rinner from Biognosys to hear more about our novel LiP-MS technology for unbiased profiling of drug binding sites across the whole proteome.

Check out this most recent Cell publication from Cappelletti et al. (ETH Zürich, Picotti Group) demonstrating our LiP-MS technology to dramatically expand proteomics ability to identify global protein structural readouts, capture enzyme activity changes, phosphorylation, and protein-protein interactions.

Have a look at this recently published GenomeWeb article to get an overview of the growing footprint of proteomics in oncology research and its impact on the various stages of drug development. The article also summarizes our recent publication in Nature Communications as well as our posters presented at ESMO, ENA and SITC 2020 congresses.